Phase 2 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a consent form agreeing to take part, or if you are not able to do this yourself, a trusted legal representative can sign on your behalf and you can show your agreement in another way.
- You have already completed the full double-blind treatment period of a specific earlier study involving the drug ML-007C-MA (study ML-007C-MA-221).
- The doctor running the trial believes you could benefit from continuing to take the study drug ML-007C-MA over a longer period of time.
- You have a designated care partner (such as a family member or caregiver) who sees or speaks with you often enough to accurately report on your symptoms and whether you are taking the study drug as directed.
- You live in a stable home setting — such as your own home, an assisted living facility, or a nursing home — and are expected to stay in that same setting for the whole duration of the study.
Who may not be able to join:
- You are currently receiving hospice care, are confined to bed, or are receiving end-of-life care.
- You need to take certain medications that are not allowed under this trial's rules.
- You have developed a new or worsening health condition during or since the earlier study that, in the doctor's opinion, could put you at risk, affect your ability to follow the study procedures, or affect how results are measured.
- You have had a significant abnormal result from a physical exam, vital signs check, heart test (ECG), or blood/lab test during or since the earlier study that could affect your safety or the study results (confirm with trial site).
- You have developed an allergy or bad reaction to the study drug ML-007C-MA or any of its ingredients since taking part in the earlier study.
- You are considered to be at an elevated risk of suicidal thoughts or behaviour.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MapLight Therapeutics, MapLight Therapeutics
Phone: +1 650 839 4380
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with AD
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.